Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...